Skip to content
Menu

Amylyx Pharmaceuticals, Inc. AMLX

Full chart Compare
Set alert

Price alert · AMLX

All alert types
26.26 USD +0.06 (+0.23%)

As ofNov 20, 2026, 2:09 PM EST

25.52 Day range 26.40
10.83 52-week range 41.14
YTD
+117.38%
1 year
+93.51%

5D -4.22 (-13.68%)

262830ThuFriMonTueWed26.62
Market cap
3.38B
EPS (ttm)
-1.43
Shares out
128.56M
Forward P/E
-22.22
YTD return
+117.38%
1-year return
+93.51%
50-day average
29.28
200-day average
20.99
Enterprise value
2.66B
Price / book
4.47
Volume
633.07K
Avg volume
1.58M
Open
25.64
Previous close
26.20
Day's range
25.52 – 26.40
52-week range
10.83 – 41.14
Beta
-0.08
Analysts
Strong Buy
Price target
43.00 (+63.7%)
Earnings date
Mar 2, 2027

Key statistics

Free cash flow
-80.52M
Total cash
768.13M
Total debt
4.94M
Return on equity
-30.06%
Short % of float
12.41%

Fundamental scorecard

4 of 25 checks passed on AMLX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
AMLX Revenue — quarterly 0
AMLX Net income — quarterly -45.49M
AMLX EPS — quarterly -0.38

Earnings

AMLX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 2, 2027Dec 30, 2026-0.36———
Nov 5, 2026Sep 30, 2026-0.38099-0.380.00+0.26%
Aug 6, 2026Jun 30, 2026-0.3609-0.39-0.03-8.06%
May 7, 2026Mar 31, 2026-0.34-0.37-0.03-8.82%
Mar 3, 2026Dec 31, 2025-0.31-0.30+0.01+3.23%
Nov 6, 2025Sep 30, 2025-0.43-0.37+0.06+13.95%

Upgrades / downgrades

AMLX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026MizuhomainOutperformOutperform
Oct 15, 2026CitigroupmainBuyBuy
Aug 27, 2026GuggenheimmainBuyBuy
Aug 19, 2026MizuhomainOutperformOutperform
Aug 19, 2026GuggenheimmainBuyBuy
Aug 19, 2026BairdmainOutperformOutperform

About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
amylyx.com

News

Your note

Sign in to keep a note on AMLX — it syncs with the Stock Master app.

Insider holders

AMLX insider holders
InsiderRelationLatest transactionDateShares held
BEDROSIAN CAMILLE LOfficerSaleSep 9, 2026278,064
COHEN JOSHUA BARRYChief Executive OfficerSaleNov 8, 20263,513,120
FIRESTONE KAREN M.DirectorConversion of Exercise of derivative securityAug 30, 2026116,900
FRATES JAMES MATTHEWChief Financial OfficerSaleNov 9, 2026400,156
KLEE JUSTIN BChief Executive OfficerSaleNov 8, 20263,513,060
MAZZARIELLO GINAOfficerSaleSep 9, 2026190,838

Institution ownership

AMLX institution ownership
Holder% heldSharesValueReported
FMR, LLC15.51%19,945,501522.57MSep 29, 2026
Perceptive Advisors Llc8.22%10,573,735277.03MSep 29, 2026
Blackrock Inc.8.06%10,368,007271.64MSep 29, 2026
TCG Crossover Management, LLC4.86%6,243,812163.59MSep 29, 2026
Driehaus Capital Management, LLC4.22%5,428,489142.23MSep 29, 2026
Janus Henderson Group Ltd.4.20%5,400,720141.50MSep 29, 2026

Fund ownership

AMLX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.45%3,154,72382.65MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.10%2,694,09370.59MSep 29, 2026
Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund1.89%2,433,20063.75MSep 29, 2026
Fidelity Securities Fund-Fidelity Small Cap Growth Fund1.65%2,115,96155.44MAug 30, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total 1.32%1,695,95944.43MSep 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio1.25%1,601,40241.96MSep 29, 2026